No Data
No Data
Oncternal Therapeutics Price Target Maintained With a $19.00/Share by HC Wainwright & Co.
Oncternal Therapeutics Price Target Maintained With a $19.00/Share by HC Wainwright & Co.
H.C. Wainwright Maintains Oncternal Therapeutics(ONCT.US) With Buy Rating, Maintains Target Price $19
H.C. Wainwright analyst Ram Selvaraju maintains $Oncternal Therapeutics(ONCT.US)$ with a buy rating, and maintains the target price at $19.According to TipRanks data, the analyst has a success rate
Oncternal Therapeutics' Positive Clinical Progress and Future Catalysts Underpin Buy Rating
Express News | Oncternal Therapeutics Inc - Initial Update on Onct-534 Safety and Efficacy Expected in Q3 2024
Express News | Oncternal Announces Enrollment Completed and Dosing Initiated for Sixth Dose Cohort of Phase 1/2 Study of Onct-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
Oncternal Therapeutics to Present in JonesTrading Healthcare Summit
SAN DIEGO, July 11, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that James
No Data